| |
Diabetic ketoacidosis (DKA)
is an acute metabolic complication of diabetes
characterized by hyperglycemia, hyperketonemia, and
metabolic acidosis. DKA occurs mostly in type 1
diabetes. It causes nausea, vomiting, and abdominal pain
and can progress to cerebral edema, coma, and death. DKA
is diagnosed by detection of hyperketonemia and anion
gap metabolic acidosis in the presence of hyperglycemia.
Treatment involves volume expansion, insulin
replacement, and prevention of hypokalemia.
DKA is most
common in patients with type 1 diabetes mellitus (DM)
and develops when insulin levels are insufficient to
meet the body's basic metabolic requirements. DKA is the
first manifestation of type 1 DM in a minority of
patients. Insulin deficiency can be absolute (eg, during
lapses in the administration of exogenous insulin) or
relative (eg, when usual insulin doses do not meet
metabolic needs during physiologic stress). Common
physiologic stresses that can trigger DKA include acute
infection (particularly pneumonia and UTI), MI , stroke,
pancreatitis, and trauma. Drugs implicated in causing
DKA include corticosteroids, thiazide diuretics, and
sympathomimetics. DKA is less common in type 2 DM, but
it may occur in situations of unusual physiologic
stress.
Pathophysiology
Insulin
deficiency causes the body to metabolize triglycerides
and muscle instead of glucose for energy. Serum levels
of glycerol and free fatty acids (FFAs) rise because of
unrestrained lipolysis, as does alanine from muscle
catabolism. Glycerol and alanine provide substrate for
hepatic gluconeogenesis, which is stimulated by the
excess of glucagon that accompanies insulin deficiency.
Glucagon also stimulates mitochondrial conversion of
FFAs into ketones. Insulin normally blocks ketogenesis
by inhibiting the transport of FFA derivatives into the
mitochondrial matrix, but ketogenesis proceeds in the
absence of insulin. The major ketoacids produced,
acetoacetic acid and β-hydroxybutyric
acid, are strong organic acids that create metabolic
acidosis. Acetone derived from the metabolism of
acetoacetic acid accumulates in serum and is slowly
disposed of by respiration.
|
Hyperglycemia
caused by insulin deficiency produces an osmotic diuresis that
leads to marked urinary losses of water and electrolytes.
Urinary excretion of ketones obligates additional losses of Na
and K. Serum Na may fall from natriuresis or rise due to
excretion of large volumes of free water. K is also lost in
large quantities, sometimes > 300
mEq/24 h. Despite a significant total body deficit of K, initial
serum K is typically normal or elevated because of the
extracellular migration of K in response to acidosis. K levels
generally fall further during treatment as insulin therapy
drives K into cells. If serum K is not monitored and replaced as
needed, life-threatening hypokalemia may develop.
Symptoms and Signs
Symptoms and
signs of DKA include those of hyperglycemia with the addition of
nausea, vomiting, and—particularly in children—abdominal pain.
Lethargy and somnolence are symptoms of more severe
decompensation. Patients may be hypotensive and tachycardic from
dehydration and acidosis; they may breathe rapidly and deeply to
compensate for acidemia (Kussmaul's respirations). They may also
have fruity breath due to exhaled acetone. Fever is not a sign
of DKA itself and, if present, signifies underlying infection.
In the absence of timely treatment, DKA progresses to coma and
death.
Acute cerebral
edema, a complication in about 1% of DKA patients, occurs
primarily in children and less often in adolescents and young
adults. Headache and fluctuating level of consciousness herald
this complication in some patients, but respiratory arrest is
the initial manifestation in others. The cause is not well
understood but may be related to too-rapid reductions in serum
osmolality or to brain ischemia. It is most likely to occur in
children < 5 yr when DKA is the
initial presentation of DM. Children with the highest BUN and
lowest Paco2 at presentation appear to be at greatest
risk. Delays in correction of hyponatremia and the use of HCO3
during DKA treatment are additional risk factors.
Diagnosis
In patients
suspected of having DKA, serum electrolytes, BUN and creatinine,
glucose, ketones, and osmolarity should be measured. Urine
should be tested for ketones. Those who appear significantly ill
and those with positive ketones should have ABG measurement. DKA
is diagnosed by an arterial pH <
7.30 with an anion gap > 12 and
serum ketones in the presence of hyperglycemia. A presumptive
diagnosis can be made when urine glucose and ketones are
strongly positive. Urine test strips and some assays for serum
ketones may underestimate the degree of ketosis because they
detect acetoacetic and not β-hydroxybutyric
acid, which is usually the predominant ketoacid.
Signs and
symptoms of a triggering illness should be pursued with
appropriate studies (eg, cultures, imaging studies). Adults
should have an ECG to screen for acute MI and to help determine
the significance of abnormalities in serum K.
Other laboratory
abnormalities include hyponatremia, elevated serum creatinine,
and elevated serum osmolarity. Hyperglycemia may cause
dilutional hyponatremia, so measured serum Na is corrected by
adding 1.6 mEq/L for each 100 mg/dL elevation of serum glucose
over 100 mg/dL. To illustrate, for a patient with serum Na of
124 mEq/L and glucose of 600 mg/dL, add 1.6 ([600-100]/100) = 8
mEq/L to 124 for a corrected serum Na of 132 mEq/L. As acidosis
is corrected, serum K drops. An initial K level
< 4.5 mEq/L indicates marked K
depletion and requires immediate K supplementation. Serum
amylase and lipase are often elevated, even in the absence of
pancreatitis (which may be present in alcoholic DKA patients and
in those with coexisting hypertriglyceridemia).
Prognosis and Treatment
Mortality rates
for DKA are between 1 and 10%. Shock or coma on admission
indicates a worse prognosis. Main causes of death are
circulatory collapse, hypokalemia, and infection. Among children
with cerebral edema, 57% recover completely, 21% survive with
neurologic sequelae, and 21% die.
The most urgent
goals are rapid intravascular volume repletion, correction of
hyperglycemia and acidosis, and prevention of hypokalemia.
Identification of precipitating factors is also important.
Treatment should occur in intensive care settings because
clinical and laboratory assessments are initially needed every
hour or every other hour with appropriate adjustments in
treatment.
Intravascular
volume should be restored rapidly to raise BP and ensure
glomerular perfusion; once intravascular volume is restored,
remaining total body water deficits are corrected more slowly,
typically over about 24 h. Initial volume repletion in adults is
typically achieved with rapid IV infusion of 1 to 3 L of 0.9%
saline solution followed by saline infusions at 1 L/h or faster
as needed to raise BP, correct hyperglycemia, and keep urine
flow adequate. Adults with DKA typically need a minimum of 3 L
of saline over the first 5 h. When BP is stable and urine flow
adequate, normal saline is replaced by 0.45% saline. When plasma
glucose falls to < 250 mg/dL, IV
fluid should be changed to 5% dextrose in 0.45% saline.
For children,
fluid deficits are estimated at 60 to 100 mL/kg body weight.
Maintenance fluids (for ongoing losses) must also be provided.
Initial fluid therapy should be 0.9% saline (20 mL/kg) over 1 to
2 h, followed by 0.45% saline once BP is stable and urine output
adequate. The remaining fluid deficit should be replaced over 36
h, typically requiring a rate (including maintenance fluids) of
about 2 to 4 mL/kg/h, depending on the degree of dehydration.
Hyperglycemia is
corrected by administering regular
insulin 0.15 unit/kg IV bolus initially, followed by
continuous IV infusion of 0.1 unit/kg/h in 0.9% saline solution.
Insulin should be withheld until serum K is
≥ 3.3 mEq/L. Insulin adsorption
onto IV tubing can lead to inconsistent effects, which can be
minimized by pre-flushing the IV tubing with insulin solution.
If plasma glucose does not fall by 50 to 75 mg/dL in the first
hour, insulin doses should be
doubled. Children should be given a continuous IV
insulin infusion of 0.1
unit/kg/h or higher with or without a bolus.
Ketones should
begin to clear within hours if insulin is given in sufficient
doses. However, clearance of ketones may appear to lag because
of conversion of β-hydroxybutyrate
to acetoacetate (which is the “ketone” measured in most hospital
laboratories) as acidosis resolves. Serum pH and HCO3
levels should also quickly improve, but restoration of a normal
serum HCO3 level may take 24 h. Rapid correction of
pH by HCO3 administration may be considered if pH
remains < 7 after about an hour of
initial fluid resuscitation, but HCO3 is associated
with development of acute cerebral edema (primarily in children)
and should not be used routinely. If used, only modest pH
elevation should be attempted (target pH of about 7.1), with
doses of 50 to 100 mEq over 30 to 60 min, followed by repeat
measurement of arterial pH and serum K.
When plasma
glucose becomes 250 to 300 mg/dL (13.88 to 16.65 mmol/L) in
adults, 5% dextrose should be added to IV fluids to reduce the
risk of hypoglycemia. Insulin dosage can then be reduced
(minimum 1 to 2 units/h), but the continuous IV infusion of
regular insulin should be maintained until the anion gap has
narrowed and blood and urine are consistently negative for
ketones. Insulin replacement may then be switched to regular
insulin 5 to 10 units sc q 4 to
6 h. When the patient is stable and able to eat, a typical
split-mixed or basal-bolus insulin regimen is begun. IV insulin
should be continued for 1 to 4 h after the initial dose of sc
insulin is given. Children should continue to receive 0.05
unit/kg/h insulin infusion until sc insulin is initiated and pH
is > 7.3.
Hypokalemia
prevention requires replacement of 20 to 30 mEq K in each liter
of IV fluid to keep serum K between 4 and 5 mEq/L. If serum K is
< 3.3 mEq/L, insulin should be
withheld and K given at 40 mEq/h until serum K is
≥ 3.3 mEq/L; if serum K is
> 5 mEq/L, K supplementation can be
withheld. Initially normal or elevated serum K measurements may
reflect shifts from intracellular stores in response to acidemia
and belie the true K deficits that almost all DKA patients have.
Insulin replacement rapidly shifts K into cells, so levels
should be checked hourly or every other hour in the initial
stages of treatment. Hypophosphatemia often develops during
treatment of DKA, but phosphate repletion is of unclear benefit
in most cases. If indicated (eg, if rhabdomyolysis, hemolysis,
or neurologic deterioration occurs), K phosphate 1 to 2 mmol/kg
of phosphate, can be infused over 6 to 12 h. If K phosphate is
given, the serum Ca level usually decreases and should be
monitored.
Treatment of
suspected cerebral edema is hyperventilation, corticosteroids,
and mannitol, but these are
often ineffective after the onset of respiratory arrest.
Last full
review/revision May 2007 by Jill P. Crandall, MD